Skip to main content Accessibility help
×
Home

Agents for the Treatment of Pseudomonas aeruginosa Infections

  • Mark Eggleston (a1)

Extract

Pseudomonas aeruginosa is the most common pathogen of Pseudomonas species. One of the most virulent organisms pathogenic to man, P aeruginosa can cause a variety of infections in humans. Despite the introduction of many new antimicrobial agents with enhanced activity against P aeruginosa, the high mortality rate associated with the organism over the past two decades continues.

Copyright

Corresponding author

PO Box 115, Wood-bridge, VA 22191

References

Hide All
1.Gessarci, C, Sur les colorations bleue el verle des linges a pansements. CH. Seances Acad Sci Serie D 1882;94:536.
2.Pollack, M, Pseudomonas aeruginosa, in Mandeli, GL, Douglas, KG Jr, Bennett, JE (eds): Principles and Practice of Infectious Diseases, ed 2. New York, John Wiley & Sons, 1979, pp 12361250.
3.Bodey, GP, Bolivar, R, Fainstein, V, et al: Infections caused by J Pseudomonas aeruginosa. Rev Infect Dis 1983;5:279313.
4.Nicas, TI, Iglewski, BH, The contribution of exoproducts lo virulence of Pseudomonas aeruginosa. Can J Microbial 1985;31:387.
5.Young, LS, The role of exotoxins in the pathogenesis of Pseudomonas aeruginosa infections. J Infect Dis 1980;142:626.
6.Pollack, M, The virulence of Pseudomonas aeruginosa. Rev Infect Dis 1984;6(suppl 3):S617.
7.Centers for Disease Control: Nosocomial infection surveillance, 1980-1982. CDC Surveillance Summaries 1983;32:1516SS.
8.Gerding, DN, Larson, TA, Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Am J Med 1985;79:17.
9.University of Minnesota Hospitals: Clin Microbiol Lab Newsl 1984;9:1.
10.Holmes, KK, Clark, H, Silverblatt, F, et al: Emergence of resistance in Pseudomonas during carbenicillin therapy. Antimicrob Agents Chemother 1969;1970:391.
11.Platt, R, Ehrlich, SL, Alarin, J, et al: Moxalactam therapy of infections caused by cephalothin-resistant bacteria: Influence of serum inhibitory activity on clinical response: acquisition of antibiotic resistance during therapy. Antimicrob Agents Chemother 1981;20:351.
12.Winston, DJ, McGrattan, MA, liusuttil, RW, Imipenem therap J of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother 1984;26:673.
13.Rubenis, J, Kozik, VM, Jackson, GG, Laboratory studies on genlamicin. Antimicrob Agents Chemother 1963;3:153.
14.Bundtzen, RW, Gerber, AU, Cohn, DL, et al: Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981;3:28.
15.Corrado, ML, Landesman, SH, Cherubin, CD, Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin and N. Formimidoyl Thicnamycin (MK 0787) against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1980;18:893.
16.Eng, RH, Smith, SM, Cherubin, C, Inoculum effect of new beta-lactam antibiotics on Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984;26:42.
17.Lesar, TS, Rotschafer, JC, Strand, LM, et al: Gentamicin dosing errors with four commonly used nomograms. JAMA 1982;248:11901193.
18.Jackson, GG, Riff, LJ, Pseudomonas bacteremia: Pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis 1971;124:185191.
19.Noone, P, Parsons, TMC, Pattison, JR. et al: Experience in monitoring genlamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974;1:477481.
20.Zaske, DE, Bootman, JL, Solem, LD, et al: Increased burn patient survival with individualized doses of genlamicin. Surgery 1982;91:142149.
21.Moore, RD, Smith, CR, Lietman, PS, The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia, J Infect Dis 1984;149:443448.
22.Eliopoulos, GM, Moellering, RC, Antibiotic synergism and antimicrobial combinations in clinical infections. Rev Infect Dis 1982;4:282.
23.EORTC International Antimicrobial Therapy Project Group: Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978;137:14.
24.Reyes, MP, El-Khatib, MRBrown, WJ, et al: Synergy between carbenicillin and an aminoglycoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum. J Infect Dis 1979;140:192.
25.Peterson, CD, Kaatz, BL, Angaran, DM, Ticarcillin and carbenicillin: A comparison. Drug Intel Clin Pharm 1977;11:482486.
26.Phaneuf, D, Neu, HC, Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin and ticarcillin. Antimicrob Agents Chemother 1979;16:625630.
27.Neu, HC, The new beta-lactamase stable cephalosporins. Ann Intern Med 1982;97:408419.
28.Baltch, AL, Smith, RP, Combinations of antibiotics against Pseudomonas aeruginosa. Am J Med 1985;79:816.
29.Boerema, J, Boll, B, Muytjens, H, et al: Efficacy and safety of ciprofloxacin in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother 1985;16:212217.
30.Wolff, M, Regnier, B, Fuldoss, C, et al: Penetration of pefloxacin into the CSF of patients with meningitis. Antimicrob Agents Chemother 1984;26:289291.
31.Eton, LJ, Harvey, L, Hixon, DL, et al: Ciprofloxacin therapy of infections caused by J Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother 1985;27:308310.
32.Mehtar, S, Drabuy, Y, Blakemore, P, Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria. Eur J Clin Microbiol 1986;5:248251.
33.Follath, F, Bindschedler, M, Wenk, M, et al: Use of ciprofloxacin in ihe treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 1986;5:236240.
34.Pennington, JE, Pseudomonas aeruginosa: Managinga virulent pathogen. Monograph from Eli Lilly and Company. New York, John Wiley & Sons Medical Group Company, 1987, pp 125.
35.Collins, MS, Roby, RE, Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. Am J Med 1984;76:168.
36.Pennington, JE, Pier, GB, Small, GJ, Efficacy of intravenous immune globulin for treatment of experimental Pseudomonas aeruginosa pneumonia. J Crit Care 1986;1:4.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed